Savara (NASDAQ:SVRA) Stock Falls 5.4% - Here's Why

Key Points

• Savara shares fell 5.4% to approximately $4.78 in Friday trading, with volume below the stock’s average daily level.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $10.00, despite one sell rating and a recent quarterly earnings miss.
• The clinical-stage biopharmaceutical company reported an adjusted loss of $0.16 per share versus expectations of a $0.14 loss. Institutional investors own approximately 87.93% of Savara’s shares, with BlackRock reporting a sizable new position.

Savara Inc. (NASDAQ:SVRA - Get Free Report) traded down 5.4% during trading on Friday. The stock traded as low as $4.78 and last traded at $4.7750. 1,487,743 shares were traded during mid-day trading, a decline of 11% from the average daily volume of 1,662,975 shares. The stock had previously closed at $5.05.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Savara in a research note on Friday, July 17th. Wall Street Zen raised Savara from a "sell" rating to a "hold" rating in a report on Saturday, September 26th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $10.00.

Savara Trading Down 5.4%

The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. The business's 50 day simple moving average is $5.39 and its 200 day simple moving average is $5.43. The stock has a market cap of $981.07 million, a P/E ratio of -8.23 and a beta of 0.20.

Savara (NASDAQ:SVRA - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). On average, analysts expect that Savara Inc. will post -0.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

Hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC increased its position in Savara by 96.5% in the 1st quarter. Renaissance Technologies LLC now owns 652,672 shares of the company's stock valued at $3,564,000 after acquiring an additional 320,572 shares in the last quarter. Deutsche Bank AG acquired a new stake in shares of Savara in the second quarter valued at approximately $5,328,000. BlackRock Inc. acquired a new stake in shares of Savara in the second quarter valued at approximately $76,966,000. Walleye Capital LLC bought a new position in Savara in the 2nd quarter worth approximately $1,532,000. Finally, Orbimed Advisors LLC bought a new position in Savara in the 1st quarter worth approximately $3,467,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.